FDA Approves Medtronic's Adaptive Deep Brain Stimulation System For Parkinson's Patients

On Monday, the FDA approved Medtronic plc’s MDT BrainSense Adaptive deep brain stimulation (aDBS) and BrainSense Electrode Identifier (EI) for patients with Parkinson’s disease.

Deep brain stimulation uses a surgically implanted neurostimulator via a minimally invasive procedure to transmit electrical signals to specific parts of the brain affected by debilitating neurological disorders.

Medtronic has enhanced its Percept DBS neurostimulators with exclusive BrainSense Adaptive technology for Parkinson’s.

Also Read: Medtronic Q3 Earnings: Cardiovascular And Neuroscience Drive Growth, Surgical Revenue Dips, Reaffirms Annual Forecast

This feature personalizes therapy based on a patient’s brain activity in real-time – both in clinical settings and daily life.

It provides enhanced therapy personalization for symptom control that automatically adjusts, minimizing the need for patients to manually adjust stimulation.

BrainSense Adaptive DBS is available to Medtronic DBS patients with Parkinson’s who have been implanted with a Percept neurostimulator and future Medtronic DBS patients.

The Medtronic Adaptive DBS Algorithm for Personalized Therapy in Parkinson’s Disease (ADAPT-PD) trial highlights the potential of aDBS in clinical practice.

The FDA approval also includes the Medtronic BrainSense Electrode Identifier (EI), which helps reduce patient time spent in clinic to program their DBS settings. Using EI, clinicians can conduct an accurate and precise initial programming, 85% faster than traditional electrode selection.

BrainSense aDBS and EI are also available in Europe. Patient programs in the United States will begin at select healthcare systems over the coming weeks, with availability nationwide in the coming months.

Price Action: MDT stock is up 0.85% at $90.70 at the last check on Monday.

Read Next:

• Apple Commits $500 Billion In US Investment For AI Push, Boost US Manufacturing Tech

Photo via Shutterstock